Sorrento Therapeutics (SRNE) Announces Its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron
- Wall Street ends mixed after punishing week
- Broadcom (AVGO) in Talks to Acquire VMware (VMW) - WSJ
- '3600 is the New Bull Case': Outflows from Energy and Materials Highest in Several Years - BofA
- Dollar catches a break after bruising week as investors turn risk averse
- Apple (AAPL) is a 'Compelling Name To Own' Right Now, iPhone Sales Trending Ahead of Guidance - Wedbush's Ives
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced its late-stage preclinical Mpro inhibitor, STI-1558, effectively inhibits Omicron virus entry and replication in cell-based assays.
The world is experiencing a huge wave of infection with the Omicron variant of SARS-CoV-2, and current vaccines and EUA-approved antibodies offer diminished protection against Omicron transmission and infection. STI-1558 is an oral Mpro inhibitor which has demonstrated in preclinical studies broad-spectrum anti-SARS-CoV-2 activity when tested for activity against the original SARS-CoV-2 strain and all previous predominant variants of concern (VOCs).
STI-1558’s antiviral activity against Omicron has also been tested in a cell-based neutralization assay. In VeroE6 cells challenged with Omicron variant, STI-1558 alone (without efflux inhibitor) showed significant antiviral activity with an EC50 value of 360 nM, equivalent activity to that seen against the Delta variant (EC50 value, 370 nM). Notably, in an Omicron S protein-mediated pseudovirus entry assay, STI-1558 effectively inhibited pseudovirus entry into cells, whereas EUA-approved nirmatrelvir showed no inhibition. Particularly, STI-1558 showed improved human liver metabolic stability as compared to nirmatrelvir, and its oral bioavailability does not depend on the ritonavir co-administration. Without the need to co-administer Ritonavir, STI-1558 potentially avoids significant adverse drug-drug interactions.
“With Omicron becoming a globally dominant variant of SARS-CoV-2 in such a short period of time, we are focused on developing an effective therapeutic strategy for fighting the Omicron variant and future variants of concern, and most importantly, for preventing or overcoming drug-resistance. Sorrento continues its commitment to develop and deliver effective anti-COVID therapies to save patient lives and end the pandemic,” stated Dr. Henry Ji, Chairman and CEO of Sorrento.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Immix Biopharma's (IMMX) IMX-110 Demonstrated Improved Survival Over FDA Approved Drug Trabectedin in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study
- Altamira Therapeutics (CYTO) Reports Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite Study
- Radius Health (RDUS) Appoints Jennifer A. Jarrett and Susan Vissers Lisa to its Board
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!